Glenmark receives ANDA approval for lidocaine ointment

It is the generic version of AstraZeneca’s Xylocaine ointment

It is the generic version of AstraZeneca’s Xylocaine ointment

Glenmark Pharmaceuticals USA (Glenmark) has been granted final approval by the United States Food & Drug Administration for Lidocaine ointment USP, five per cent , the generic version of Xylocaine Ointment, five per cent of AstraZeneca.

According to IMS Health sales data for the 12 month period ending July 2016, the Xylocaine ointment, five per cent market achieved annual sales of approximately $373.0 million.

Glenmark’s current portfolio consists of 109 products authorised for distribution in the US marketplace and 62 ANDA’s pending approval with the US FDA.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express Telegram Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.